Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.

Astellas Pharma’s chief commercial officer discusses the biopharma industry’s responsibility to drive change in health care.

In this episode of the In Vivo podcast, Hakim Yadi, CEO and co-founder of UK techbio Closed Loop Medicine, discusses how the company is pairing software and predictive analytics with medications old and new to tailor drug dosing.  

Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024.

In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

One of In Vivo's 2024 Rising Leaders, Hanadie Yousef, CEO of Juvena Therapeutics, talks about the secretome as a source of therapeutics, the company's lead assets, the future of longevity medicine and learning as you go as a biotech entrepreneur.  

Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.